Citigroup Inc Beam Therapeutics Inc. Call Options Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 12, 2024	SELL	$21.22 - $32.66 $528,378 - $813,233	-24,900 Reduced 49.9%	25,000 $585,000
Q1 2024 May 10, 2024	BUY	$23.46 - $45.07 $586,500 - $1.13 Million	25,000 Added 100.4%	49,900 $1.65 Million
Q4 2023 Feb 09, 2024	BUY	$17.69 - $30.76 $440,481 - $765,924	24,900 New	24,900 $677,000
Q1 2023 May 11, 2023	BUY	$30.15 - $48.79 $48,240 - $78,064	1,600 Added 10.06%	17,500 $535,000
Q4 2022 Feb 09, 2023	BUY	$36.73 - $51.6 $584,007 - $820,440	15,900 New	15,900 $621,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.